Invion Ltd.ASX: IVX

Oesophageal Cancer Collaboration and Funding Agreement

· Issued by Invion Ltd.

Filed with ASX · · 3 pages · English

Summary by 6ix AI

Hanlim will fund pre-clinical studies for both oesophageal cancer and glioblastoma, while Invion retains rights to its Photosoft™ technology and any new intellectual property from the collaboration. This partnership aims to address the urgent need for new treatments for oesophageal cancer, which currently has a high mortality rate and limited effective therapies. The collaboration enhances Invion's position in targeting multiple high-need cancers by leveraging Hanlim's resources and expertise.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Invion Ltd. on 6ix

Story so far

Earlier from Invion

Later from Invion

All Invion news releases